Navigation Links
Study identifies possible new target for future brain cancer drugs
Date:2/27/2014

COLUMBUS, Ohio A molecule in cells that shuts down the expression of genes might be a promising target for new drugs designed to treat the most frequent and lethal form of brain cancer, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James).

The findings, published in the journal Cancer Research, show that high levels of the enzyme PRMT5 are associated with aggressive growth of the brain cancer glioblastoma multiforme (GBM). The malignancy strikes nearly 14,000 Americans annually. It is a highly invasive form of cancer that is difficult to remove entirely by surgery. Following surgery, chemotherapy and radiation, average survival is still only 15 months, pointing to a critical need for new treatments.

This study shows that inhibiting PRMT5 can significantly improve survival in an animal model of GBM. Blocking the enzyme inhibited the growth, proliferation and migration of GBM cells in laboratory studies, and it increased the number of GBM cells that died by apoptosis.

"Our findings suggest that PRMT5 is a possible prognostic factor and therapeutic target for glioblastoma, and they provide a rationale for developing agents that target PRMT5 in this deadly disease," says co-corresponding author Robert A. Baiocchi, MD, PhD, associate professor of medicine and a hematologist at the OSUCCC James who is also collaborating on an Ohio State effort to develop a PMRT5 inhibitor.

"Our analyses also helped us identify PRMT5 as a master transcriptional repressor (gene silencer) in this disease, says co-corresponding author Balveen Kaur, PhD, professor of Neurological Surgery at the OSUCCC James.

"We also learned that PRMT5 inhibition induced the death of glioblastoma cells whether the P53 gene was mutated or not. This has important treatment implications because loss of P53 is associated with a poor prognosis in these patients, so a PRMT5 inhibitor might be particularly important for these patients," says Kaur, who is specializes in glioblastoma research and is chief of Ohio State's Dardinger Laboratory of Neurosciences.

PRMT5 (protein arginine methyltransferase 5) is an enzyme that alters the structure of chromatin to suppress the transcription of genes and the production of proteins. To conduct their study, Kaur, Baiocchi and their colleagues used tumor tissue from patients, cell lines and an animal model. Key findings included:

  • PRMT5 is selectively over-expressed in glioblastoma and the degree of PRMT5 expression correlates with cell growth and patient survival.
  • In GBM patients, PRMT5 expression levels in tumor were significantly associated with lower overall survival;
  • Patients with high PRMT5 tumor expression had shorter overall survival (108 days) compared to patients with medium expression (277 days) and low expression (726 days).


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Wexner Medical Center
Source:Eurekalert

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Study reveals how cancer drug causes diabetic-like state
3. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
4. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
5. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
6. No Added Cancer Risk From Hip Replacement Materials: Study
7. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
8. Early Study Finds Some Promise for Lung Cancer Vaccine
9. Narcissists Often Ace Job Interviews, Study Finds
10. Sexual objectification of female artists in music videos exists regardless of race, MU study finds
11. Soy may alleviate hot flashes in menopause, large-scale study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... California (PRWEB) , ... June ... ... pioneer in the patient payment industry today announced its strategic partnership with ... health system workflows. , The two companies’ proven, proprietary technology combine to ...
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... environments  Oticon , industry leaders in ... the launch of Oticon Opn ™, the world,s ... world of possibilities for IoT devices.      ... Opn, Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology: